Vcanbio Cell & Gene Engineering , Ltd Goodwill

Vcanbio Cell & Gene Engineering , Ltd (600645.SS) currently reports a goodwill of $700M as of June 2026. That compares with $700M in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Vcanbio Cell & Gene Engineering , Ltd's goodwill history and peer comparisons.

Vcanbio Cell & Gene Engineering , Ltd's goodwill was unchanged from $700M to $700M — essentially flat versus a year earlier (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vcanbio Cell & Gene Engineering , Ltd reported $700M in goodwill as of June 2026. That compares with $700M in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $700M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vcanbio Cell & Gene Engineering , Ltd, and consider following 600645.SS for alerts when major investors trade the stock.

Vcanbio Cell & Gene Engineering , Ltd is classified in the Healthcare sector. On goodwill, it currently shows $700M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 600645.SS with unrelated industries.